When the Liquid API Must Be Adsorbed before High-Shear Wet Granulation

Because 3-iodobenzotrifluoride remains a liquid at standard handling temperatures with a density of 1.887 g/mL at 25 °C, direct addition to a wet granulation feed without an adsorption step produces granule over-wetting and punch sticking. No pharmacopoeia monograph for this compound is listed in USP or Ph. Eur.; therefore specification justification follows ICH Q6A Decision Tree #1 for identity, assay, and impurity control. In screening batches for oral tablet cores, the liquid API is adsorbed onto Neusilin US2 at a loading ratio of 0.8–1.2 g/g carrier; after mixing with microcrystalline cellulose, crospovidone, and colloidal silicon dioxide, the API mass fraction in the final granulate is reduced to 5.0–10.0% w/w, with tablet core concentration held at 0.5–3.0% w/w pending toxicology batch confirmation. Granulation is performed in a 65 L high-shear granulator with impeller speed 350 rpm, chopper speed 1500 rpm, and purified water addition at 18–22% w/w of the dry charge; the wet mass is screened through a 1.0 mm mesh and dried in a fluid-bed drier at 45–50 °C to a loss-on-drying value of 1.5–2.0%. Tableting on a 16-station rotary press with 8 mm shallow-concave tooling uses compression force 12–18 kN, target hardness 60–90 N, friability not more than 0.5% by USP <1216>, and content uniformity by USP <905>. Dissolution is tested by USP <711> with an aqueous surfactant medium; elemental impurities are assessed per ICH Q3D, and production follows 21 CFR 210/211. The terminal finished product type is a film-coated immediate-release tablet, packaged in opaque blisters to limit C–I photolytic degradation.

Hard gelatin capsule filling lines equipped with positive-displacement liquid dosing pumps accommodate this compound without prior solid-state conversion, because the API is miscible with medium-chain triglycerides and propylene glycol monocaprylate-type vehicles. In liquid-filled hard capsule feasibility batches, the fill mass is standardized at 450–500 mg for size 0 capsules, and the API concentration is limited to 1.0–3.0% w/w of the fill mass to avoid shell softening and longitudinal seam cracking. Compliance testing follows USP <711> dissolution and USP <905> uniformity of dosage units; residual solvent control uses USP <467> and ICH Q3C. The manufacturing process requires a jacketed stainless-steel compounding vessel held at 45–50 °C, recirculation through a 500 µm screen, and high-shear dispersion at 5,000–8,000 rpm for 15–20 min. Filling on a dosator-free liquid pump with nozzle diameter 0.8–1.2 mm and fill temperature not exceeding 55 °C maintains weight variation below 3% RSD; capsules are sealed with HPMC-based banding. Production-scale failure modes include nozzle drip after 8–10 h of continuous operation, which has caused fill-weight variation above 4% unless nozzle retraction and drip evacuation are initiated. The terminal finished product type is a liquid-filled hard gelatin capsule in aluminum/PVC cold-form blister packaging.

What Limits Direct Compression of Liquisolid Compacts at Process Speeds Above 30 rpm?

Direct compression is feasible only after the liquid API is converted into a free-flowing liquisolid powder with a carrier-to-coating ratio above 20:1; below this threshold, punch sticking and weight variation exceed 2.5% RSD on a 16-station rotary press. The addition ratio set during feasibility work uses microcrystalline cellulose PH-200 at 10.0–20.0% w/w of the final blend, fumed silica at 0.5–1.5% w/w, and liquid API at 1.5–4.0% w/w after pre-dilution in 0.5–1.0% w/v ethanol to reduce viscosity. Powder flow is verified by USP <1174> and Ph. Eur. 2.9.36; compressibility index must remain below 20%, and Hausner ratio below 1.25. Compression at speeds above 30 rpm has produced capping at 12 kN because the high-surface-area carrier does not undergo sufficient plastic deformation within the shortened dwell time; reducing speed to 20–25 rpm and using 8 mm flat-faced bevel-edged punches maintains tablet hardness at 50–80 N. If ambient humidity exceeds 60% RH, fumed silica is pre-dried at 100 °C for 2 h before blending to prevent flow decay. The release package includes USP <905> content uniformity, USP <711> dissolution, and ICH Q3D elemental impurities. The terminal finished product type is an immediate-release tablet manufactured by direct compression, suited to continuous or semi-continuous solid-dosage lines with low-humidity enclosure.

Oral granule formulations using a 2-hydroxypropyl-β-cyclodextrin inclusion complex are processed by vacuum-drying rather than spray-drying to limit photolytic degradation of the C–I bond and to avoid thermal stress at elevated inlet air temperatures. The complex is prepared at an API:HPβCD molar ratio of 1:2 to 1:4, with complexation yield confirmed by differential scanning calorimetry; final granule API concentration is held at 0.5–2.0% w/w to maintain dose flexibility for reconstituted oral suspension. Purified water containing 10–15% w/w ethanol is added to form a paste, which is extruded through an 0.8 mm screen and vacuum-dried at 40 °C for 6–8 h to residual moisture ≤1.0%. Dried granules are classified through 500 µm and 1.25 mm sieves; the 500–1,250 µm fraction is filled into aluminum sachets under ≤10% RH conditions and sealed under nitrogen. Compliance standards include ICH Q3D elemental impurities, Ph. Eur. 5.1.3 antimicrobial preservation if the reconstituted suspension is intended for multi-dose use, and USP <711> dissolution with aqueous surfactant medium. The terminal finished product type is granules for oral suspension, reconstituted with water or a buffered vehicle immediately before administration.

Oil-Based Injectable Solution Stability and Filter Sterilization

For parenteral administration, the liquid API is compounded into hydrophobic vehicles because water solubility is below 0.1 mg/mL at 25 °C; aqueous solution requires cyclodextrin or co-solvent systems that are assessed separately under ICH Q8. Aqueous buffers containing primary amines are excluded from screening because the C–I bond is susceptible to nucleophilic substitution under alkaline pH. In oil-based injectable screening, ethyl oleate or medium-chain triglycerides serve as the primary vehicle, and the API concentration is set at 1.0–5.0% w/v (10–50 mg/mL). The vehicle is filtered through a 0.22 µm PVDF membrane under nitrogen pressure, then mixed with API in a jacketed stainless-steel vessel at 35–40 °C with overhead impeller mixing at 300–500 rpm for 30–45 min. Terminal sterilization uses 0.22 µm PVDF membrane filtration rather than autoclaving at 121 °C, because thermal degradation kinetics for the C–I bond in oil have not been qualified; if autoclaving is mandated, a terminal sterilization validation must include degradation bracketing per ICH Q1E. Release testing includes USP <1> Injections, USP <71> Sterility Tests, USP <85> Bacterial Endotoxins, and ICH Q3D elemental impurities. Vials are filled to 1 mL or 5 mL volumes in Type I amber glass under Grade A/B conditions. Published data for this specific oil-based configuration is limited; therefore, each strength and pack must be bracketed for peroxide formation and photolytic stability. The terminal finished product type is an injectable solution in a Type I amber glass ampoule or vial.

Lyophilized powder for injection is manufactured via a phospholipid-stabilized emulsion that separates the liquid API from the ice-crystal interface during freezing, reducing the risk of vial breakage and heterogeneous drying. The pre-lyophilization emulsion contains egg phosphatidylcholine at 1.2% w/v, sucrose or trehalose at 5.0% w/v, and API at 0.1–1.0% w/v; the aqueous phase is prepared separately and passed through a high-shear rotor-stator homogenizer at 15,000 rpm for 10 min, followed by microfluidization at 10,000–15,000 psi for 3–5 cycles. The resulting emulsion is filtered through 0.45 µm and then 0.22 µm membranes, filled into Type I glass vials, and lyophilized with a shelf program that freezes at −40 °C for 4 h, primary dries at −20 °C under 150 mTorr for 24 h, and secondary dries at +30 °C for 6 h. Residual moisture is controlled to ≤1.0% w/w by Karl Fischer titration, and the lyophilized cake is sealed under nitrogen in amber glass. Compliance includes ICH Q3D, USP <905> for uniformity of dosage units, USP <71> sterility, and USP <85> bacterial endotoxins. The terminal finished product type is a lyophilized powder for reconstitution into injection; the diluent must be selected to maintain complete solubility after reconstitution.